Dr. Anton Buzdin is a professor at I.M. Sechenov First Moscow State Medical University and the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry. He graduated from Moscow State University and defended his PhD thesis in molecular biology at the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry. He worked as the CEO of several international biotech and biomed companies. He also served as Chief Scientific Officer at Pathway Pharmaceuticals (Hong Kong), Insilico Medicine (USA), and Omicsway (USA). Now, he heads several research laboratories, supervises 26 international employees, and runs projects on molecular oncology, immunology, and clinical bioinformatics at Sechenov First Moscow Medical University, Shemyakin–Ovchinnikov Institute, Moscow Institute of Physics and Technology, and Omicsway (USA). Since April 2021, he has served as Chair of the Biostatistics and Bioinformatics subgroup, Pathobiology Group, European Organization for Research and Treatment of Cancer (EORTC), and is a Specialty Chief Editor (Cancer Genetics and Oncogenomics) of the journal Frontiers in Genetics. He is also a visiting professor at Johannes Gutenberg University Mainz.